FDA posted three drug GMP warning letters this week to pharmaceutical firms, one to a compounding pharmacy, one to a GLP site, and two to device manufacturers. CDRH appears to have come alive again after a very slow 2019.

Regarding the device warning letters, several were posted on the FDA site for an hour or so, and dated April 7 (I don’t know why they would pre-date this, that’s a longer discussion about data integrity). I was able to grab a couple before they were taken down, hopefully, the others will appear next week with the correct date, or at least not be pre-dated again.

And finally, the FDA continues to issue warning letters to firms that are distributing unapproved products to treat COVID-19 disease.

DRUGS | Ficosota LTD (Bulgaria)

The firm received a warning letter on February 28, 2020, based on the outcome of an inspection ending September 5, 2019. FDA placed the OTC firm on Import Alert 66-40 on January 10, 2020. FDA also recommended that the firm hire a qualified consultant to assist them in coming into CGMP compliance. Even with a consultant, FDA notes that “Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.”

The firm’s quality systems are deemed to be inadequate and they lack an ongoing program for monitoring processes to ensure they remain in a state of control. Overall the FDA deemed the firm’s response to be inadequate because it did not include any details on corrective actions nor did it include analysis of the effect the identified deficiencies may have on a product already distributed in the US. This latter shortcoming is one that is almost becoming boilerplate in recent warning letters.

Deficiencies include but aren’t limited to:

  • The firm failed to perform appropriate QC testing prior to the distribution of products to the US market. This includes identity and strength testing for the active ingredient in the drug product.
  • The firm failed to test incoming raw materials including API, but rather accepted results on the certificate of analysis. Further, the suppliers were not qualified and the firm did not confirm the reliability of the results on the CoA, either initially or on a periodic basis.
  • The Quality Unit is inadequate and has failed to perform basic responsibilities including failure to approve and reject API and drug products; ensure testing is performed and reviewed prior to batch release; failure to review and approve MBRs and PBRs and ensure they included sufficient detail.
  • The stability program does not require long term evaluation for the drug product. The expiry date was 3 years even though the stability program did not include adequate physicochemical and microbiological attribute evaluations to justify that dating. The firm could only provide limited data to support the 3-year expiry.

DRUGS | Trilogy Laboratories, LLC (Fort Myers, FL)

Trilogy Laboratories, LLC received a warning letter on March 5, 2020, based on the outcome of an inspection ending August 27, 2019. The firm “manufactures, repackages, distributes or sells” sunscreens and other products which appear to be in the cosmetics and OTC category.

The firm’s response to the form 483 was inadequate and did not include an evaluation of the impact of the deficiencies on the product currently on the market and within expiry. The warning letter included three GMP deficiencies along with a litany of “unapproved new drug” and “misbranding” violations. The firm has ceased production at this facility and FDA advises them they need to notify FDA prior to re-starting production.

Deficiencies include but aren’t limited to:

  • The firm does not perform adequate tests of drug product prior to release including, but not limited to, identity and strength testing for APIs.
  • The firm did not validate the vendor CoA results at periodic intervals and did not identity test each component upon receipt.
  • The firm has not established and implemented adequate procedures to ensure that products have the identity, strength, quality, and purity they are represented to have. 

DRUGS | Pfizer Healthcare India Private Limited (Visakhapatnam, India)

The Chairman and CEO of Pfizer, based in NY, received a warning letter on March 25, 2020, based on the outcome of an inspection at a sterile injectable drug manufacturing site in India ending September 6, 2019.  This site was a part of the Hospira acquisition several years ago. These sites have proven to be nothing but an ongoing headache for Pfizer with remediation that just never seems to adequately take hold and warning letters that continue to be issued. FDA states “Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture.” FDA acknowledged the firm is hiring a consultant to audit their operations and assist in meeting GMP requirements.

Deficiencies include but aren’t limited to:

  • The firm failed to conduct adequate investigations and implement effective CAPA actions. The deficiency focused on two areas: sterility failures and the environmental monitoring program.
    • Regarding the sterility failures, it appears there may have been due to a “lack of robust [container closure] integrity testing and possible non-integral drug product vials.” Corrective changes were not implemented until several lots later. The firm committed to inspecting sterility test samples for integrity prior to testing. FDA felt that other corrective actions were not timely in its implementation. Further, the response to the form 483 did not include the revised investigation and the status of progress on the corrective and preventive actions.
    • Regarding the environmental monitoring program, the firm did not adequately investigate shortcomings in the microbiology laboratory conditions and practices. Common problems included an excessive number of negative control plate contamination, EM data that were not considered because of delays in reading the plates, and high levels of contamination in EM samples for sterility tests. The firm also did not have documentation of earlier readings performed before the extended incubation times. FDA noted that lab data accuracy was a deficiency cited in an inspection from September 2018, thus this is a repeat deficiency. This seems like a laboratory that is not operating in a state of control.

GLP (Pre-clinical Animal Studies) | Steiner Biotechnology LLC (Henderson, NV)

Steiner Biotechnology received a warning letter on February 3, 2020, based on the outcome of a BIMO inspection ending June 28, 2019. The inspection was conducted regarding their activities supporting the Skeletal Graft and Ridge Graft devices. No mention is made of the sponsor.

Deficiencies include but aren’t limited to:

  • Studies were not conducted consistent with protocols.
  • Multiple surgeries were conducted on animals yet none of the protocols called for this. Some animals were used in multiple studies, though the study protocol states that animals will not be used in multiple studies. The firm provided a justification for this practice but the FDA did not accept their reasons and provided a detailed explanation for rejecting this response.
  • Anesthesia used in the surgeries was not the one specified in the protocol. The firm’s response that their research veterinarian deemed the anesthesias adequate was not accepted by the FDA along with FDA’s reasons.
  • The Quality Unit failed to meet its responsibilities as described in 21CFR5835(b)(3) and (c). Checklists that were used during periodic evaluation by the Quality Unit were inadequate and did not identify all activities that should be considered. Further, the firm did not have written documentation of the responsibilities and procedures for the Quality Unit.
  • Specimens collected were not properly labeled as specified in the regulations. Two were labeled only with an animal number written on the side of the container or the lid, and in other cases, several samples were located in the same container without appropriate identification.  While the firm committed to correctly identify samples, they did not address how this violation would be prevented in the future.
  • The FDA investigator was unable to obtain complete and current training records for staff who participated in the studies in question.  

DEVICES | E-Care Technology Corp (Taiwan)

E-Care Technology Corp received a warning letter on March 2, 2020, based on the outcome of an inspection ending October 25, 2019.

Deficiencies include but aren’t limited to:

  • The firm did not document design configurations used in the testing of the devices. Further, the report issued for this component of design control validation did not include the lot number or other means to identify the device(s) used in the validation study.
  • Inspection, measuring, and test equipment are not demonstrated to be suitable for its intended use and to generate valid results.
  • The firm does not have a means of receiving complaints regarding products sold in the US by private-label customer(s).
  • The firm has not ensured that sampling methods are adequate and reviewed when changes occur.

DEVICES | Okamoto Rubber Products Co., Ltd. (Thailand)

Okamoto Rubber Products Co., Ltd received a warning letter on February 14, 2020, based on the outcome of an inspection ending November 7, 2019.  The firm manufactures lubricated natural rubber condoms.

Deficiencies include but aren’t limited to:

  • The firm has not validated the rework process permitted in their procedures.
  • CAPA procedure(s) have not been adequately developed, maintained and followed.
  • Sampling methods are not demonstrated to be adequate for their intended use.

HCT/P | Dynamic Stem Cell Therapy (Henderson, NV)

Dynamic Stem Cell Therapy received an untitled letter on April 1, 2020, based on the review of their website and Facebook page. They market cellular products that are advertised to treat a range of medical conditions including COVID-19 infections. Likely, that may be how they caught the FDA’s attention. This untitled letter was not based on an inspection of their manufacturing or clinical site.

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.